Dr Reddy’s Laboratories announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) injection, in the US market approved by the US Food and Drug Administration (USFDA).
The Velcade Brand and generic had US sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.
Bortezomib for injection is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma
Dr Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.